Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALADIN II study of long-acting octreotide in autosomal dominant polycystic kidney disease with moderate to severe renal insufficiency
2009-012376-27Phase 3Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Nov 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Octreotide with Placebo (2 arms). Primary endpoint: Total kidney volume change. Started Nov 2009; status: terminated.
02
Drugs
octreotide
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2009-012376-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012376-27.